SG10201700916SA - Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof - Google Patents

Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Info

Publication number
SG10201700916SA
SG10201700916SA SG10201700916SA SG10201700916SA SG10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA
Authority
SG
Singapore
Prior art keywords
listerial
expression
preparation
methods
signal peptide
Prior art date
Application number
SG10201700916SA
Other languages
English (en)
Inventor
Peter M Lauer
William G Hanson
Justin Skoble
Meredith Lai Ling Leong
Marcella Fasso
Dirk Brockstedt
Thomas W Dubensky Jr
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of SG10201700916SA publication Critical patent/SG10201700916SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201700916SA 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof SG10201700916SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US201361780744P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201700916SA true SG10201700916SA (en) 2017-03-30

Family

ID=51017446

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201700916SA SG10201700916SA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
SG11201502792TA SG11201502792TA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201502792TA SG11201502792TA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Country Status (12)

Country Link
US (2) US9663557B2 (enExample)
EP (1) EP2938627B1 (enExample)
JP (2) JP2016503655A (enExample)
KR (1) KR102160322B1 (enExample)
CN (1) CN104955835B (enExample)
AU (2) AU2013370210B2 (enExample)
BR (1) BR112015015076A2 (enExample)
CA (1) CA2888727A1 (enExample)
EA (1) EA201590397A8 (enExample)
MX (1) MX2015008329A (enExample)
SG (2) SG10201700916SA (enExample)
WO (1) WO2014106123A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
KR20140134695A (ko) 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해
MA40344A (fr) 2014-07-18 2016-01-21 Advaxis Inc Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US10765699B2 (en) 2015-02-06 2020-09-08 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
MA44378A (fr) 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
KR20180002640A (ko) * 2015-04-13 2018-01-08 아두로 바이오테크, 인코포레이티드 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법
EP3298031B1 (en) * 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
CN114751950B (zh) * 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
CN111247241A (zh) 2017-08-10 2020-06-05 新加坡国立大学 T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
EP3762719A1 (en) 2018-03-09 2021-01-13 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of listeria strains
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
CA3184128A1 (en) 2020-06-23 2021-12-30 Kathleen Barnes Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
EP1303299B1 (en) * 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
AU2001290860A1 (en) 2000-09-21 2002-04-02 The Regents Of The University Of California Spas-1 cancer antigen
WO2003102168A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
US20050281783A1 (en) 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
EP2860253B1 (en) 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2008008311A1 (en) 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
CN102076843A (zh) * 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
SI2640842T1 (sl) 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
CA2829960A1 (en) * 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
KR20140134695A (ko) * 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해

Also Published As

Publication number Publication date
EP2938627A4 (en) 2016-12-14
SG11201502792TA (en) 2015-05-28
AU2013370210B2 (en) 2018-06-14
JP6671408B2 (ja) 2020-03-25
WO2014106123A1 (en) 2014-07-03
BR112015015076A2 (pt) 2018-10-30
KR20150099738A (ko) 2015-09-01
EP2938627B1 (en) 2019-03-20
EP2938627A1 (en) 2015-11-04
US20170253637A1 (en) 2017-09-07
WO2014106123A8 (en) 2016-06-16
US9663557B2 (en) 2017-05-30
AU2018203555A1 (en) 2018-06-07
CN104955835A (zh) 2015-09-30
US20140186387A1 (en) 2014-07-03
CA2888727A1 (en) 2014-07-03
HK1215260A1 (zh) 2016-08-19
EA201590397A1 (ru) 2016-02-29
EA201590397A8 (ru) 2016-08-31
JP2018135355A (ja) 2018-08-30
CN104955835B (zh) 2020-04-17
JP2016503655A (ja) 2016-02-08
AU2013370210A1 (en) 2015-06-18
MX2015008329A (es) 2016-03-01
AU2013370210A8 (en) 2016-06-23
KR102160322B1 (ko) 2020-09-25

Similar Documents

Publication Publication Date Title
SG11201502792TA (en) Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
ZA201502991B (en) Disubstituted amino acids and methods of preparation and use thereof
ZA201404962B (en) Modified mini-hepcidin peptides and methods of using thereof
IL241787B (en) Human fcrn-binding modified antibodies and methods of their use
SI2945647T1 (sl) Imunogeni peptidi WT-1 in postopki za uporabo le-teh
SI2581389T1 (sl) Fuzijski protein eksendina-4 in njegov analog, metoda priprave in njena uporaba
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
SG10201601621PA (en) Serpin fusion polypeptides and methods of use thereof
IL236738A0 (en) Human antibodies to gfra3 and methods of using them
EP3080607A4 (en) Novel anti-dpep3 antibodies and methods of use
ZA201404712B (en) Composite antigenic sequences and vaccines
IL233481A0 (en) Peptides and methods of using them
SMT201800512T1 (it) Anticorpi specifici per il polipeptide amiloide degli isolotti umano(hiapp) e relativi usi
EP3029072A4 (en) Glp-1 analog fusion protein and preparation method and use thereof
IL241418A0 (en) Improved methods of use for recombinant human secretoglobins
HUS2200014I1 (hu) Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
EP2996718A4 (en) E1e2 hcv vaccines and methods of use
EP3078677A4 (en) Antigen chimera, antigen combination, vaccine, method of preparing same, and kit thereof
GB2503388B (en) Sealing ring and preparation method thereof
SG10201506857QA (en) Method of synthesizing peptides, proteins and bioconjugates
IL239671A0 (en) Stable form of fusion proteins of signal transducing protein, and methods for their use and preparation
IL245273A0 (en) Long-acting polypeptides and methods for their preparation and administration
IL237719A0 (en) Antibodies specific to (hiapp) human islet amylid polypeptide and their uses